Tom De Potter, EHRA 2018 – First-in-human results of ultra-low-temperature continuous ablation
Tom De Potter (OLV Hospital, Aalst) discusses the aims of recent trials on ultra-low-temperature continuous ablation and summarises the results, which showed that the system is highly efficacious in an acute setting. Although long-term outcomes are yet to be determined, the results so far show promise in terms of meeting the ultimate goal of achieving electrical block, with 95% acute isolation rates in the first-in-human setting. In terms of safety, Dr De Potter explains, the findings from the studies were also excellent.
Filmed at EHRA 2018, Barcelona.
Questions:
1. What are that advantages of ultra-low-temperature continuous ablation compared with other ablation approaches? 0:07
2. Please summarise the top-line efficacy data from the first-in-human study of ultra-low-temperature continuous ablation for the treatment of paroxysmal and persistent atrial fibrillation and atrial flutter? 1:03
3. Please describe the top-line safety findings from the first-in-human study of ultra-low-temperature continuous ablation for the treatment of paroxysmal and persistent atrial fibrillation and atrial flutter. 1:54